News
We send the latest information from SMC Laboratories.
Introducing our new model: Liver Orthotopic Xenograft mouse model
We’re getting in touch today with an announcement regarding the addition of the Liver Orthotopic Xenogra…
Our clients’ presentations at DDW 2021
Our clients presented data on treatment of NASH using STAMTM model at the DDW2021 (May 21-23). For deta…
SMC announces Presentation of New Data at the 81st Annual Meeting of the American Diabetes Association
We are pleased to announce the acceptance of our abstract, “RNA-seq Analysis of Liver from Diabetic and …
Visit SMC Laboratories at BIO Digital 2021
We are joining the world’s largest virtual biotech partnering and education event, convening thousands o…
New Partnership with cancer model search service Repositive, Inc.
SMC Laboratories, Inc. is pleased to announce a partnership with Repositive, Inc., a UK-based bespoke cancer m…
Amplia Therapeutics has publshed a pres releaes regarding the AMP945 and AMP886 efficacy evaluation study for NASH we have provied.
Amplia Therapeutics, which is our client, has announced the results of pharmacology study using a STAM™ …
Chemomab announces enrollment of first patient in phase 2a study of CM-101 in NASH
Chemomab Ltd.(Israel) announced on 26 April, 2021, enrollment of first patient in phase 2a study of CM-101 in …
Pre-clinical studies for cirrhosis: Carbon tetrachloride (CCl4)-induced liver fibrosis
The CCl4-induced liver fibrosis model is a model that forms bridging fibrosis around the portal vein region. W…
Wnt/β-catenin in our NASH-HCC model: How does it correlate to human liver cancer?
The main cause of hepatocellular carcinogenesis today is chronic liver disease following HCV and HBV infection…
CohBar, Inc. announces the completion of enrolment in the Phase 1b stage of the CB4211 clinical study of NASH and obesiy.
CohBar, Inc. (USA) announced on March 29, 2021, that the completion of enrolment in the Phase 1b stage of the …